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The Changing Landscape of Vestibular Schwannoma Diagnosis
and Management: A Cross-Sectional Study
Khodayar Goshtasbi, BS; Mehdi Abouzari, MD, PhD; Omid Moshtaghi, MD, MS ; Ronald Sahyouni, PhD;
Autefeh Sajjadi, MS; Harrison W. Lin, MD; Hamid R. Djalilian, MD
Objectives: To assess the current state of the diagnosis and management of vestibular schwannoma (VS) as well as treatment
trends, and to evaluate the role of treatment setting and various specialists in treatment plan.
Methods: Patients diagnosed with VS completed a voluntary and anonymous survey. The questionnaires were distributed
through Acoustic Neuroma Association website, Facebook page, and e-mail newsletters from January to March 2017.
Results: In total, 789 VS patients completed the survey. Of those, 414 (52%) underwent surgery; 224 (28%) underwent
radiotherapy; and 121 (15%) were observed. General otolaryngologists diagnosed 62% of responders, followed by primary
care (11%) and neurotologists (10%). Patients who underwent surgery were significantly younger and had larger tumors com-
pared to those treated with radiation or observation. The ratio of patients having nonsurgical versus surgical resection changed
from 1:2 to 1:1 for the periods of 1979 through 2006 versus 2007 through 2017, respectively. Neurosurgeons (40%) and
neurotologists (38%) were the most influential in treatment discussion. Neurotologists (P < 0.001) and general otolaryngolo-
gists (P = 0.04) were more influential than neurosurgeons for the decision process in patients with smaller tumors. Patients
treated at academic versus nonacademic private institutions reported similar tumor sizes (P = 0.27), treatment decisions
(P = 0.09), and decision satisfaction (P = 0.78).
Conclusion: There is a continuing trend toward nonsurgical management, with approximately half of the patients opting
for nonsurgical management. In this cohort, the patients commonly presented with otologic symptoms and otolaryngologists
made the most diagnoses. Neurotologists and neurosurgeons were the most influential in treatment discussion.
Key Words: Vestibular schwannoma, acoustic neuroma, treatment trend, influential specialist, decision satisfaction.
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INTRODUCTION
Vestibular schwannomas (VS) are benign tumors
arising from the eighth cranial nerve and comprising 6%
to 8% of all intracranial tumors.1,2 Whereas the annual
incidence of 1.1 to 1.7 per 100 thousand people has re-
mained steady, tumors have been diagnosed at smaller
sizes over time.3–6 After diagnosis, VS patients are faced
with a multifaceted decision-making process to manage their
tumor via watchful observation, radiotherapy, or surgical
resection. Retrospective studies of large cohorts demon-
strated that 48% to 59% of patients underwent microsur-
gery, and 21% to 24% underwent radiotherapy, with surgical
resection correlating with younger age and larger tumor
size.3,5,6 With innovations in imaging and radiotherapy,
some authors have begun to advocate for the benefits of
observation and radiotherapy over surgical treatment.3,7–10
However, a review of VS treatment demonstrated that selec-
tion bias and confounding factors, such as age and pre-
treatment status, limit comparing efficacy and safety across
treatment modalities.11
It is yet unclear whether the rise in advocacy for con-
servative management is independent from the earlier
detection of these tumors at smaller sizes. Both diagnosis
and treatment of VS are continuously evolving toward
greater collaboration between neurotologists, neurosur-
geons, and radiation oncologists, among others.12–14 How-
ever, the specific roles and influence of these providers in
diagnosis and treatment discussion have yet to be com-
pared. This patient-centered study aims to assess the cur-
rent state of diagnosis and management of VS, as well as
to evaluate the role of treatment setting and various spe-
cialists’ influence in treatment plan and satisfaction.
MATERIALS AND METHODS
In collaboration with the Acoustic Neuroma Association
(ANA) and after institutional board approval from the University
of California, Irvine, a comprehensive and anonymous survey
was distributed to all ANA members from January to March
2017 using a secure and confidential REDCap interface
(Vanderbilt University, Nashville, TN).15 The link to the survey
was available on the ANA website https://www.anausa.org/ and
Facebook page https://www.facebook.com/ANAssociation/; in
addition, notification was sent via e-mail to listed ANA members.
A VS diagnosis was required to participate in the study. Survey
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questions were mostly in the following formats: free response,
choosing the best answer, or checking all that apply. The survey
evaluated patients’ demographics, diagnosis information includ-
ing involved physicians and VS tumor characteristics, treatment
modality with the associated course and outcome, treatment cen-
ters, and influential specialists contributing to treatment.
Patients’ eventual treatments were categorized into surgery,
radiation, watchful observation, surgery–radiation combination,
and undecided. The latter two treatments were excluded from
some analyses due to a low response rate. Surgery cohort consisted
of patients undergoing complete or incomplete resection; radiation
cohort consisted of patients receiving stereotactic radiosurgery or
radiotherapy; and watchful observation patients underwent serial
magnetic resonance imaging (MRI) scans. In this article, we define
conservative (nonsurgical) management as either radiation or
watchful observation. Because most questions were optional to
answer, not all number breakdowns in tables add up to 100% of
the respective cohort.
PASW Statistics 18.0 software (SPSS Inc., Chicago, IL) was
used for statistical analysis, with a 0.05 alpha considered significant.
Independent sample t test and chi-square test were used for numeri-
cal and categorical variables, respectively. Univariate analysis of
variance (ANOVA) was used to compare numerical variables among
different cohorts; those that demonstrated a significant P value were
further analyzed for subset comparison via Bonferroni’s correction.
Lastly, when comparing the treatments of patients diagnosed since
2007 versus those prior to that, the potential confounding effect of
their tumor size at diagnosis was determined via a bivariate analysis
using binary (surgery or conservative) or multinomial (surgery, radi-
ation, or observation) logistic regression.
RESULTS
Demographics and Diagnosis
In total, 789 individuals diagnosed with VS completed
the survey, with an average age at diagnosis of 52.0  11.8
years. Patients’ demographics and different treatment
modalities are summarized in Table I. The tumor size diag-
nosed by different specialists and eventual treatments are
compared in Table II. One-way ANOVA showed a significant
difference between specialists in diagnosed tumor size
(P = 0.003). Multiple comparison analysis revealed that
tumors diagnosed by general otolaryngologists (P = 0.012)
and neurotologists (P = 0.004) were smaller than those diag-
nosed by neurosurgeons. There was no difference in treat-
ment decision (i.e., surgery or nonsurgical management)
when comparing patients diagnosed by different specialists
(P = 0.607).
Whereas 60 (7.6%) patients had their tumors found
incidentally, 726 (92.0%) patients obtained MRI due to con-
cerning symptoms on presentation. The most common symp-
toms were hearing loss (n = 559, 70.8%), imbalance/
dizziness (n = 304, 38.5%), tinnitus (n = 295, 37.4%), aural
fullness (n = 232, 29.4%), and vertigo (n = 152, 19.3%). Over-
all, 704 (89.2%) patients experienced at least one of these
symptoms.
Treatment Trend
One-way ANOVA showed that the surgically treated
patients were younger and had larger tumor sizes com-
pared to those treated with radiation (both P < 0.001) or
observation (both P < 0.001). In Table III, participants diag-
nosed between 2007 and 2017 (n = 580) were compared to
those diagnosed prior to 2007 (n = 209) regarding tumor
size at diagnosis and eventual treatment. Tumor size at
diagnosis was smaller in the 2007 through 2017 cohort com-
pared to the 1979 through 2006 period (1.87 vs. 2.33 cm,
P = 0.013). The former cohort underwent surgery in 47.1%
(n = 273) of cases versus nonsurgical management in 48.1%
(n = 279) of cases. This was significantly different than
those diagnosed between 1979 and 2006, with 66.0%
(n = 138) surgical and 31.1% (n = 65) nonsurgical patients
(P < 0.001). When we adjusted for tumor size as a possible
confounder, there still was a significant difference between
nonsurgical versus surgical management of the two time
periods (P = 0.002).
Specialists and Treatment Centers
During the course of VS management, 700 (87.8%) pa-
tients had seen a neurosurgeon, 549 (68.9%) a neurotologist,
307 (38.5%) a radiation oncologist, and 39 (4.9%) a general
otolaryngologist. Patients were asked which specific special-
ist played the most influential role in the discussion and
decision of treatment. Of the 759 responders, 301 (39.7%)
designated neurosurgeons, 287 (37.8%) neurotologists,
77 (10.1%) general otolaryngologists, and 50 (6.6%) radia-
tion oncologists. Average tumor sizes were 2.34  1.39,
1.79  1.13, 1.88  1.22, and 1.87  1.26 cm, respectively
(P < 0.001). Post hoc analysis showed that neurotologists
(P < 0.001) and general otolaryngologists (P = 0.04)
were most influential in smaller tumor sizes compared
to neurosurgeons.
Of those who specified their treatment setting
(n = 684), 411 (60.1%) patients received treatment at aca-
demic institutions, 259 (37.9%) at private nonacademic
medical centers, and 14 (2.0%) at the Veteran Adminis-
tration hospitals. There were no significant differences in
treatment decision (P = 0.09), tumor size at diagnosis
(P = 0.27), days of hospitalization (P = 0.05), or discussion
of most influential specialist in treatment (P = 0.36)
between academic and private nonacademic centers’ pa-
tients. On a scale of 1 to 5, there was no difference
(P = 0.78) in satisfaction, with treatment decision between
receiving treatment at academic (3.87  1.1) versus private
nonacademic (3.85  1.1) institutions.
TABLE I.
Vestibular Schwannoma Patients’ Demographics.
Treatment
Modality N (%)
Tumor Size
(SD) in cm
Age at
Diagnosis
(SD)
Female
Sex (%)
Years Since
Diagnosis (SD)
Surgery 414 (52.5) 2.38 (1.33) 48.6 (11.3) 285 (68.8) 8.4 (8.4)
Radiation 224 (28.4) 1.72 (1.10) 55.6 (11.1) 139 (62.1) 6.3 (5.1)
Observation 121 (15.3) 1.12 (0.88) 57.2 (10.3) 73 (60.3) 5.4 (5.1)
Surgery +
radiation
14 (1.8) 2.98 (1.31) 42.4 (13.0) 9 (64.3) 5.2 (2.9)
Undecided 16 (2.0) 1.70 (1.18) 56.9 (7.5) 11 (73.3) 3.5 (5.6)
Total 789 (100) 2.02 (1.28) 52.0 (11.8) 517 (65.5) 7.2 (7.1)
SD = standard deviation.
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DISCUSSION
This patient-centered study of VS patients demon-
strates that there is a trend toward nonsurgical manage-
ment even when adjusted for the decreasing tumor size at
diagnosis. The patients mostly presented with otologic symp-
toms and were diagnosed by otolaryngologists. Neurosur-
geons and neurotologists were perceived as the most
influential in discussing treatment, and patients reported no
meaningful differences between the treatment institutions.
Diagnosis
The common clinical symptoms experienced in VS
patients are reported as hearing loss (57%–95%), tinnitus
(12%–83%), vertigo/dizziness (14%–75%), and trigeminal
neuropathy (4%–9%).16–20 These wide ranges are partly
due to the heterogeneity of tumor size and location (intra-
canalicular vs. mostly in cerebellopontine angle). Hearing
loss was seen in most of our cohort (71%) who underwent
initial diagnostic MRI, but tinnitus and imbalance/dizziness
(both 38%) also represented a significant number of com-
plaints leading to imaging. It is important to note that our
five most common presenting symptoms were all otologic-
related. This is in agreement with our breakdown of diagnos-
ing physicians, in which otolaryngologists and neurotologists
were identified as having diagnosed more than 70% of the
VS cases.
We also found that tumors diagnosed by neurosur-
geons were larger than those diagnosed by neurotologists
and general otolaryngologists. It may be because VS starts
manifesting itself with otologic symptoms and thus naturally
draws the patient to otolaryngologists, as opposed to neuro-
surgeons who may receive referrals after a large enough
tumor has led to enoughmass effect for neurologic symptoms
or an emergency department setting. Although not signifi-
cant, we observed that patients diagnosed by neurosurgeons
received slightly higher rates of radiosurgery and lower rates
of surgery despite the fact they were shown to have larger
average tumor size. This might be due to some neurosur-
geons’ higher level of comfort with radiosurgery versus surgi-
cal resection or the setting of their practice.
Treatment
Participants who underwent surgical resection were
younger and had larger tumor sizes, which is consistent
with other studies.3,5,6 Our mean age at diagnosis
(52.0 years) was comparable to a large epidemiological
study (53.1 years),5 but our average tumor size (1.12 cm)
was consistent with that reported from a large meta-
analysis (1.18 cm).8 When separating the cohort into
recently diagnosed (2007–2017) patients and those diag-
nosed prior to 2007, we observed a different treatment
breakdown. Namely, nonsurgical management has be-
come more prevalent from a previous 1:2 (nonsurgical to
surgical) ratio to the 1:1 of the recent decade. This is con-
sistent with the current body of literature suggesting the
consideration of observation and radiation therapy for the
appropriate tumors, which is due to earlier detection, more
diagnoses in elderly patients with indolent tumors, better
monitoring, limited number of regrowth in VS tumors, and
avoiding surgical-related complications.3,9,10,21–24
The cohort diagnosed in 2007 through 2017 had a
smaller tumor size at diagnosis, but we showed that there
was a persisting trend toward nonsurgical management
even after adjusting for tumor size. It has been suggested
that tumors ≤3 cm in the cerebellopontine angle are
potential candidates for radiosurgery and that observa-
tion can show success for slow-growing and smaller VS
TABLE III.
Comparison of Patients Diagnosed Within Last 10 Years Versus
Those Diagnosed Previously Regarding Tumor Size and Eventual
Treatment.
Diagnosing Window
2007–2017 1979–2006 P Value
N (% total) 580 (73.3%) 209 (26.2%)
Tumor size (SD) 1.87 (1.24) 2.33 (1.41) 0.013
Treatment modality <0.001*
Surgery 273 (47.1%) 138 (66.0%)
Radiation 179 (30.9%) 45 (21.5%)
Observation 100 (17.2%) 20 (9.6%)
Undecided and surgery-plus-radiation patients were excluded from
treatment modality’s analyses.
*P value remained significant after adjusting for size as a potential
confounder via multinomial binary logistic regression (P < 0.001).
SD = standard deviation.
TABLE II.
Initial Specialist Diagnosing Vestibular Schwannomas and Respective Frequency, Average Tumor Size, and Eventual Treatment Modality.
N (% of 749*)
Diagnosing Physician
P Values
Otolaryngologist
486 (61.6%)
PCP
85 (10.8%)
Neurotologist
81 (10.2%)
Neurosurgeon
69 (8.7%)
Neurologist
28 (3.5%)
Tumor size (SD) 1.94 (1.28) 2.15 (1.41) 1.72 (1.06) 2.50 (1.28) 2.21 (1.16) 0.003
Treatment modality 0.372
Surgery 253 (52.1%) 39 (45.9%) 43 (53.1%) 33 (47.8%) 18 (64.3%)
Radiation 131 (27.0%) 24 (28.2%) 20 (24.7%) 25 (36.2%) 5 (17.9%)
Observation 77 (15.8%) 13 (15.3%) 15 (18.6%) 5 (7.2%) 3 (10.7%)
*749 is the number of responders that participated in this question. Undecided and surgery-plus-radiation patients were excluded from treatment
modality’s analyses.
PCP = primary care physician; SD = standard deviation.
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tumors, especially <2 cm total length.3,9,22,25–27 A portion of
the surgical patients in this study, especially those diag-
nosed prior to 2007, fall within these ranges. This suggests
that some of these patients could have benefitted from a dis-
cussion regarding conservative management as a viable
option. Alternatively, it is also important to point out recent
emerging evidence suggesting a possible association of poor
long-term hearing outcomes with conservative management.
Evidence from modern, conformal, low-dose radiation tech-
niques demonstrated poor long-term hearing preservation
rates, from 80% to 23% in 2-year and 10-year posttreatment
hearing preservation rates, respectively.28 Likewise, a 2018
study not included in this review showed a similar trend in
466 conservatively managed patients, demonstrating a drop
of 94% to 44% in 1-year and 10-year serviceable hearing
maintenance rates (defined as pure tone average ≤50 dB
hearing loss and word recognition score ≥50%).29 A 2019
literature review and institutional experience of hearing
preservation surgery on small vestibular schwannomas con-
cluded that, although observation may have better short-
term hearing function, active surgical treatment can offer a
better chance of long-term hearing preservation.30 With the
trend toward smaller tumor size at diagnosis, all treatment
options—including risks and benefits associated with each—
should be discussed with patients whose tumor characteris-
tics renders them candidates for such approaches.
Influential Specialists and Treatment Centers
Our data showed that neurosurgeons were closely
followed by neurotologists as the most influential specialists
in treatment discussion. Otolaryngologists or neurotologists
who were most influential in almost half of the patients had
patients with smaller tumor sizes compared to those diag-
nosed by neurosurgeons. Of those who specified their treat-
ment setting, 60% were treated at academic institutions
compared to 38% receiving treatment at private non-
academic institutions. A geographical analysis of access
to cancer care centers suggested that 50% and 75% of the
U.S. population live within less than 30 minutes of aca-
demic and private facilities providing cancer care, respec-
tively.31 This implies that, although more people are likely
to live close to a private institution, most of our cohort sought
treatment at an academic center. Studies suggest that many
baseline confounders may be present, including age, socio-
economic status, ethnicity, baseline morbidity, or hospital
caseloads, rendering simple comparison challenging.32–34
Regardless, we demonstrated that this study’s patients
receiving care at academic and nonacademic private
institutions had similar eventual treatment distribution
and satisfaction with this decision.
Limitations
Although great effort was taken to ensure the validity
of our findings, this study relied on retrospective self-
reported data and lacked a control group. Moreover, diagno-
sis and management may be influenced by factors and
confounders beyond the scope of this study, such as patients
or physicians’ subjective preferences, access to care, and
outside influencers like online resources or family and
support groups. The patient–physician relationship and the
perception of bedside manners, knowledge, and time spent
can vary from case to case as well.35 Participation bias may
also play a role because ANA members active in the online
community were more likely to access and spend time com-
pleting the survey. Also, it is plausible to consider that
patients with either poor or excellent outcomes may be
more inclined to participate. The ANA members may also
be socioeconomically different than the general population of
VS patients. Lastly, some of the participants completed the
survey a long time after their initial diagnosis and treat-
ment, which can lead to recall bias. In addition to recall bias,
this difference of range of time from diagnosis/treatment to
survey participation can influence the diagnosis and treat-
ment regimens because the standard-of-care guidelines may
be determined or changed by the time period. Regardless of
these limitations, this study’s large cohort and extensive
questions can offer additional insight, especially from the
patients’ perspective.
CONCLUSION
We found that patients diagnosed with VS from 2007
through 2017 had smaller tumor sizes, along with an in-
crease in nonsurgical management. Otologic symptoms were
the most common presenting symptoms in VS patients;
accordingly, general otolaryngologists and neurotologists
diagnosed the majority of patients. Patient treatment deci-
sion was influenced the most by neurosurgeons when tumor
size was larger or by otolaryngologists and neurotologists
when the tumor size was smaller. Although more patients
sought care at an academic center, treatment decision or sat-
isfaction was similar to that at private institutions.
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